IP Library Granted Patent US 9,427,407
Granted Patent B2
US 9,427,407 · App. 14/748,621 · Granted Aug 30, 2016

Pharmaceutical compositions

Inventor: Paul Bosse (Jupiter, FL)
Assignee: LOCL PHARMA, INC.
A61K9/209A61K9/20A61K9/2086A61K31/167A61K31/485A61K31/5415A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,427,407
App. No.
14/748,621
Granted
Aug 30, 2016
Kind
B2
Abstract

Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic.

Claims (44)

1. A method for treating pain, and reducing or preventing nausea or vomiting associated with an opioid analgesic, the method comprising administering a solid oral pharmaceutical composition to a subject in need thereof, wherein the solid oral pharmaceutical composition comprises:

a layer formulated for immediate-release comprising an antiemetic, wherein the antiemetic is promethazine or a pharmaceutically acceptable salt thereof that is present in an amount of about 12.5 mg or 25 mg; and

a layer formulated for controlled-release comprising an opioid analgesic that is present in an amount of 1 mg to about 20 mg and a non-opioid analgesic that is present in an amount of about 200-600 mg,

wherein the solid oral pharmaceutical composition provides an effective amount of the antiemetic to reduce or prevent nausea associated with the opioid analgesic or vomiting associated with the opioid analgesic in the subject in need thereof, and an effective amount of the opioid analgesic and the non-opioid analgesic to treat pain in the subject in need thereof.

2. The method of claim 1 , wherein the promethazine or the pharmaceutically acceptable salt thereof is present in an amount of about 12.5 mg.

3. The method of claim 1 , wherein the promethazine or the pharmaceutically acceptable salt thereof is present in an amount of 25 mg.

4. The method of any one of claims 2 or 3 , wherein the pharmaceutically acceptable salt of the promethazine is promethazine hydrochloride.

5. The method of claim 1 , wherein the pharmaceutically acceptable salt of the promethazine is promethazine hydrochloride.

6. The method of claim 1 , wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof, or oxycodone or a pharmaceutically acceptable salt thereof.

7. The method of claim 6 , wherein the opioid analgesic is hydrocodone bitartrate.

8. The method of claim 6 , wherein the opioid analgesic is oxycodone hydrochloride.

9. The method of claim 1 , wherein the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the solid oral pharmaceutical composition is a bi-layer tablet.

11. A method for treating pain, and reducing or preventing nausea or vomiting associated with an opioid analgesic, the method comprising administering a solid oral pharmaceutical composition to a subject in need thereof, wherein the solid oral pharmaceutical composition comprises:

a layer formulated for immediate-release comprising a single antiemetic; and

a layer formulated for controlled-release comprising a non-opioid analgesic and an opioid analgesic, wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof, or oxycodone or a pharmaceutically acceptable salt thereof, and the opioid analgesic is present in an amount of about 1 mg to about 15 mg, and wherein the non-opioid analgesic is present in an amount of about 200-600 mg,

wherein the solid oral pharmaceutical composition provides an effective amount of the antiemetic to reduce or prevent nausea associated with the opioid analgesic or vomiting associated with the opioid analgesic in the subject in need thereof, and an effective amount of the opioid analgesic and the non-opioid analgesic to treat pain in the subject in need thereof.

12. The method of claim 11 , wherein the opioid analgesic is hydrocodone or the pharmaceutically acceptable salt thereof, and is present in an amount of about 7.5 mg.

13. The method of claim 11 , wherein the opioid analgesic is hydrocodone or the pharmaceutically acceptable salt thereof, and is present in an amount of 5 mg.

14. The method of claim 12 , wherein the opioid analgesic is hydrocodone bitartrate.

15. The method of claim 11 , wherein the opioid analgesic is oxycodone or the pharmaceutically acceptable salt thereof, and is present in an amount of about 7.5 mg.

16. The method of claim 11 , wherein the opioid analgesic is hydrocodone bitartrate.

17. The method of claim 11 , wherein the opioid analgesic is oxycodone hydrochloride.

18. The method of claim 11 , wherein the antiemetic is promethazine or a pharmaceutically acceptable salt thereof.

19. The method of claim 18 , wherein the antiemetic is promethazine hydrochloride.

20. The method of claim 11 , wherein the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof.

21. The method of claim 11 , wherein the solid oral pharmaceutical composition is a bi-layer tablet.

22. A method for treating pain, and reducing or preventing nausea or vomiting associated with an opioid analgesic, the method comprising administering a solid oral pharmaceutical composition to a subject in need thereof, wherein the solid oral pharmaceutical composition comprises:

a layer formulated for immediate-release comprising an antiemetic that is present in an amount of about 12.5 mg or 25 mg; and

a layer formulated for controlled-release comprising an opioid analgesic and a non-opioid analgesic, wherein the opioid analgesic is present in an amount of 1 mg to about 20 mg, and wherein the non-opioid analgesic is acetaminophen or a pharmaceutically acceptable salt thereof that is present in about 200-600 mg,

wherein the solid oral pharmaceutical composition provides an effective amount of the antiemetic to reduce or prevent nausea associated with the opioid analgesic or vomiting associated with the opioid analgesic in the subject in need thereof, and an effective amount of the opioid analgesic and the non-opioid analgesic to treat pain in the subject in need thereof.

23. The method of claim 22 , wherein the acetaminophen or the pharmaceutically acceptable salt thereof is present in an amount of about 325 mg.

24. The method of claim 22 , wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof, or oxycodone or a pharmaceutically acceptable salt thereof.

25. The method of claim 24 , wherein the opioid analgesic is hydrocodone bitartrate.

26. The method of claim 24 , wherein the opioid analgesic is oxycodone hydrochloride.

27. The method of claim 22 , wherein the antiemetic is promethazine or a pharmaceutically acceptable salt thereof.

28. The method of claim 27 , wherein the antiemetic is promethazine hydrochloride.

29. The method of claim 22 , wherein the solid oral pharmaceutical composition is a bi-layer tablet.

30. The method of claim 15 , wherein the pharmaceutically acceptable salt of the oxycodone is oxycodone hydrochloride.

31. The method of claim 11 , wherein the oxycodone or the pharmaceutically acceptable salt thereof is present in an amount of 5 mg.

32. The method of claim 31 , wherein the pharmaceutically acceptable salt of the oxycodone is oxycodone hydrochloride.

33. The method of claim 1 , wherein the solid oral pharmaceutical composition further comprises an opioid antagonist or an additional agent for reducing abuse and/or diversion.

34. The method of claim 11 , wherein the solid oral pharmaceutical composition further comprises an opioid antagonist or an additional agent for reducing abuse and/or diversion.

35. The method of claim 22 , wherein the solid oral pharmaceutical composition further comprises an opioid antagonist or an additional agent for reducing abuse and/or diversion.

Assignments (3)
CHANGE OF ADDRESS Recorded Dec 9, 2015
From: LOCL PHARMA, INC.
To: LOCL PHARMA, INC.
Reel/Frame 037255/0606 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2015
From: BOSSE, PAUL
To: CHARLESTON LABORATORIES, INC.
Reel/Frame 035895/0546 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2015
From: CHARLESTON LABORATORIES, INC.
To: LOCL PHARMA, INC.
Reel/Frame 035895/0560 →
Continuity (6)
Continuation 14099432 · Dec 6, 2013
Continuation 12444521
Provisional Application 60948375 · Jul 6, 2007
Provisional Application 60921563 · Apr 3, 2007
Provisional Application 60850451 · Oct 9, 2006
Related Publication 20150328213A1 · Nov 19, 2015